| payload |
{"created_at":"2026-04-21T03:09:54.871 {"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:79b5b19f763e3632","evidence_event_ids":["evt_0017d4a5ee31"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","company":"Verrica Pharmaceuticals Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_93a3d4ce70dcec64","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","content_type":"text/plain","enriched_at":"2026-04-21T05:55:01.805586+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt","source_event_id":"evt_0017d4a5ee31","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"5bd21a4e8f2694fb","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-06-05","2026-04-08","2026-04-20","2026-04-21"],"entities":[{"asset_class":"equity","name":"Verrica Pharmaceuticals Inc.","relevance":"high","symbol":"VRCA","type":"issuer"},{"asset_class":"other","name":"SEC","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"Equiniti Trust Company, LLC","relevance":"medium","symbol":"","type":"transfer_agent"}],"event_type":"listing","information_gaps":["What the \u201cfour matters scheduled for a vote\u201d are is not included in the provided text excerpt (only referenced as being described in the accompanying proxy statement).","The signal is described as a \u201cdelta,\u201d but no prior known state or comparison content is provided in the prompt, so the specific change vs prior state cannot be determined from the excerpt.","No financial guidance or financial implications are disclosed in the provided text excerpt."],"key_facts":["Form DEF 14A was filed for Verrica Pharmaceuticals Inc. (VRCA).","The annual meeting of stockholders is scheduled for Friday, June 5, 2026 at 10:00 a.m. local time.","The meeting location is the Company\u2019s headquarters at 44 W. Gay St., Suite 400, West Chester, Pennsylvania 19380.","The record date for the annual meeting is April 8, 2026.","Only stockholders of record at the close of business on April 8, 2026 are entitled to notice of and to vote at the meeting or any adjournment.","On the record date, there were 17,178,786 shares of common stock outstanding and entitled to vote.","The Company elected to provide access to proxy materials over the internet pursuant to SEC rules and intends to mail the Notice on or about April 20, 2026.","The proxy statement indicates the Board is soliciting proxies to vote at the 2026 Annual Meeting, including any adjournments or postponements.","The notice states there are four matters scheduled for a vote, and the proxy statement accompanying the notice describes them more fully."],"numeric_claims":[{"label":"Annual meeting date","value":"2026-06-05"},{"label":"Annual meeting time","value":"10:00 a.m. local time"},{"label":"Record date","value":"2026-04-08"},{"label":"Common shares outstanding entitled to vote (record date)","value":"17,178,786"}],"primary_claim":"Verrica Pharmaceuticals Inc. filed a DEF 14A proxy statement for its 2026 annual meeting of stockholders, scheduled for June 5, 2026 with an April 8, 2026 record date.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Verrica Pharmaceuticals Inc. filed its 2026 proxy statement on Form DEF 14A, providing notice and details for its annual meeting of stockholders. The filing states the meeting will be held June 5, 2026 and sets an April 8, 2026 record date for voting.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting of stockholders","voting record date","internet availability of proxy materials"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Verrica Pharmaceuticals Inc. \u00b7 Filed 20260420","ticker":"VRCA","tickers":["VRCA"],"title":"VRCA filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-163961.txt"}}... |